PreserFlo MicroShunt Outcomes in Asia: Two-Year Results with Exploratory Comparisons of Standalone and Combined Surgery from a Regional Tertiary Centre
5 affiliations
- 1Singapore National Eye Centre, Singapore 168751, Singapore
- 2UCL Institute of Ophthalmology, University College London, London EC1V 9EL, UK
- 3Singapore Eye Research Institute, Singapore 169856, Singapore
- 4Duke-NUS Medical School, Singapore 169857, Singapore
- 5NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1V 2PD, UK
Abstract
Background/Objectives: To evaluate the two-year efficacy and safety of PreserFlo MicroShunt (PMS) implantation in an Asian cohort with primary open-angle glaucoma via post hoc exploratory comparison of standalone PMS versus combined phacoemulsification and PMS (PMS+Phaco). Methods: This prospective single-centre cohort study included 30 consecutive eyes of 30 patients who underwent PMS implantation and were followed for 24 months. Nine eyes underwent standalone PMS and 21 underwent PMS+Phaco. The primary outcome was surgical success assessed using Kaplan–Meier survival analysis. Qualified success was defined as intraocular pressure (IOP) of 6–21 mmHg with ≥20% reduction from baseline, with or without IOP-lowering medication; complete success required no glaucoma medications. Failure was defined as not meeting success criteria at two consecutive visits, with the earliest failure at 3 months. WGA-style definitions were retained to ensure comparison with the published literature. Results: Median age was 73 years (IQR 70–78), baseline IOP was 16.0 mmHg (14.0–18.4), and patients were using a median of 3 (2–3) IOP-lowering medications. At 24 months, median IOP was 15.0 mmHg (13.0–17.1), with 57% of eyes remaining medication-free. Whole-cohort qualified success at 24 months was 36.7% (95% CI 20.1–53.4). Qualified success was 44.4% (95% CI 13.6–71.9) for standalone PMS and 33.3% (14.9–53.1) for PMS+Phaco (log-rank p = 0.586). Using alternative IOP thresholds, 83.2% of eyes achieved qualified success at IOP < 18 mmHg and 76.5% did so below the cohort baseline mean of 16.5 mmHg. Corneal oedema was more frequent after combined surgery (38.1% vs. 0%). Bleb needling was required in 40% of eyes. Conclusions: PMS implantation, performed alone or with phacoemulsification, was associated with sustained reduction in medication burden, with 57% of eyes remaining medication-free at 24 months. Absolute IOP control over 24 months was modest. In post hoc exploratory analysis, no difference in surgical success was detected between procedural approaches; however, confidence intervals were wide and data were insufficient to establish equivalence. Low success rates using conventional criteria likely reflect the cohort’s relatively low baseline IOP (median 16.0 mmHg).
Related
- AS-OCT–Based Biomarkers of Early Postoperative Bleb Morphology May Predict Surgical Success After PRESERFLO MicroShunt Implantation
- Scleral Allograft-Reinforced Cyclodialysis Combined with Phacoemulsification or Performed as a Standalone Procedure: 24-Month Outcomes from the Multicenter CREST Study
- Surgical Revision of Deep Brain Stimulation After Suboptimal Clinical Outcomes: A Systematic Review and Exploratory Meta-analysis
- Predicting 1-year outcomes after anterior cruciate ligament reconstruction from preoperative physical performance using machine learning: an exploratory study
- Tinnitus outcomes after cochlear implantation in single-sided deafness: an exploratory prospective multicenter study
BibTeX
@article{ansari2026preserflo,
title = {{PreserFlo MicroShunt Outcomes in Asia: Two-Year Results with Exploratory Comparisons of Standalone and Combined Surgery from a Regional Tertiary Centre}},
author = {Abdus Samad Ansari and Yamon Thant Syn and Phey Feng Lo and Zhu Li Yap and Paul J. Foster and Shamira A. Perera and Tina T. Wong},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15207791},
url = {https://www.mdpi.com/2077-0383/15/20/7791},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - PreserFlo MicroShunt Outcomes in Asia: Two-Year Results with Exploratory Comparisons of Standalone and Combined Surgery from a Regional Tertiary Centre
AU - Abdus Samad Ansari
AU - Yamon Thant Syn
AU - Phey Feng Lo
AU - Zhu Li Yap
AU - Paul J. Foster
AU - Shamira A. Perera
AU - Tina T. Wong
PY - 2026
DA - 2026/10/01
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15207791
UR - https://www.mdpi.com/2077-0383/15/20/7791
AB - Background/Objectives: To evaluate the two-year efficacy and safety of PreserFlo MicroShunt (PMS) implantation in an Asian cohort with primary open-angle glaucoma via post hoc exploratory comparison of standalone PMS versus combined phacoemulsification and PMS (PMS+Phaco). Methods: This prospective single-centre cohort study included 30 consecutive eyes of 30 patients who underwent PMS implantation and were followed for 24 months. Nine eyes underwent standalone PMS and 21 underwent PMS+Phaco. The primary outcome was surgical success assessed using Kaplan–Meier survival analysis. Qualified success was defined as intraocular pressure (IOP) of 6–21 mmHg with ≥20% reduction from baseline, with or without IOP-lowering medication; complete success required no glaucoma medications. Failure was defined as not meeting success criteria at two consecutive visits, with the earliest failure at 3 months. WGA-style definitions were retained to ensure comparison with the published literature. Results: Median age was 73 years (IQR 70–78), baseline IOP was 16.0 mmHg (14.0–18.4), and patients were using a median of 3 (2–3) IOP-lowering medications. At 24 months, median IOP was 15.0 mmHg (13.0–17.1), with 57% of eyes remaining medication-free. Whole-cohort qualified success at 24 months was 36.7% (95% CI 20.1–53.4). Qualified success was 44.4% (95% CI 13.6–71.9) for standalone PMS and 33.3% (14.9–53.1) for PMS+Phaco (log-rank p = 0.586). Using alternative IOP thresholds, 83.2% of eyes achieved qualified success at IOP < 18 mmHg and 76.5% did so below the cohort baseline mean of 16.5 mmHg. Corneal oedema was more frequent after combined surgery (38.1% vs. 0%). Bleb needling was required in 40% of eyes. Conclusions: PMS implantation, performed alone or with phacoemulsification, was associated with sustained reduction in medication burden, with 57% of eyes remaining medication-free at 24 months. Absolute IOP control over 24 months was modest. In post hoc exploratory analysis, no difference in surgical success was detected between procedural approaches; however, confidence intervals were wide and data were insufficient to establish equivalence. Low success rates using conventional criteria likely reflect the cohort’s relatively low baseline IOP (median 16.0 mmHg).
SN - 2077-0383
ER -